Integrative Oncology Therapy Research Association
Versione italiana
Subscribe Our Newsletter

Your Name (requested)

Your email (requested)

I accept the Privacy Policy

Watch Us on YouTube
Find Us On Facebook
External Links


The development of inhibitors of protein farnesyl transferase, such as R115777 and lonafarnib, is derived from the observation that the ras protein to acquire its biological properties, must be activated by farnesyl transferase. In a phase I study the administration of R115777 in patients with advanced solid tumors has been effective. The antineoplastic activity of lonafarnib was evaluated in phase I studies, either in monotherapy or in combination with chemotherapy, with good tolerability and efficacy.